Researchers from University of Adelaide suggest that obesity is responsible for the results of the most widely used test for prostate cancer.
According to The Journal of the American Medical Association (JAMA), 37.9% of people over 20 years of age are obese in U.S. and the condition is associated with multiple chronic medical problems and numerous hormonal changes leading to prostate cancer development and progression. The research led by medical oncologist Dr. Adel Aref from the University’s Adelaide Medical School, analyzed the data of around 950 men for effects of obesity on PSA levels detected in blood and the influence of the hormones, testosterone and estrogen. It was observed that it was a significant risk factor for prostate cancer death. The researchers found that high levels of prostate specific antigen (PSA) in the blood reveals the existence of prostate cancer and aids in further diagnosis of the disease. Testosterone in men is increased by PSA. However, the lowering rate of PSA in blood was attributed to obesity in men resulting in less concentrations of circulating testosterone. The study results are expected to boost the understanding of interpretation of PSA levels in men suffering from obesity.
In another experiment with animals fat intake was correlated with prostate cancer risk however, with less extent. It reveals that fat content itself was not responsible for contributing to prostate cancer. The process of preparation of the food and the toxins formed during the process were also involved in carcinogenesis. Moreover, total fat intake was related to the risk of several prostate cancer death. Both the facts relate dietary fat and prostate cancer with a stronger prevalence of prostate cancer death. The research was also supported by Freemasons Foundation Centre for Men’s Health and the Adelaide Medical School at the University of Adelaide and South Australian Health and Medical Research Institute (SAHMRI). The study published in the Society for Endocrinology on June 25, 2018 is vital for detecting and treating several other cancers in men.